Plus   Neg

Nanogold Treatment In The Making For Prostate Cancer

lightwaves 090419 lt

Prostate cancer is one of the most common cancers in men. Studies have shown that 1 in 9 men on average, is diagnosed with prostate cancer during his lifetime.

A first-in-human trial, which evaluated Nanospectra Biosciences' investigational device AuroLase in men with low-to-intermediate grade tumors within the prostate, has yielded positive results.

The AuroLase therapy involves intravenous administration of laser-excited gold-silica nanoparticles, called AuroShells. These AuroShells get accumulated within the solid tumor tissue when administered and the tumor is illuminated with a near-infrared laser. When exposed to the laser, these nanoparticles were able to ablate tumor tissues in a controlled manner, causing only minimum side effects.

If all goes well as planned, the company hopes to gain FDA clearance for its AuroLase device by the middle of 2021.

Let's take a look at the drugs that passed muster with the FDA in August 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT